Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy

Assessment of oral midazolam limited sampling strategies to predict area under the concentration time curve (AUC) during cytochrome P450 (CYP) 3A baseline, inhibition and induction or activation

(2011) J.D. Ma et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam

(2010) Stephanie Katzenmaier et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Effect of Simultaneous Induction and Inhibition of CYP3A by St John's Wort and Ritonavir on CYP3A Activity

(2009) V Hafner et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of Different Durations of Ketoconazole Dosing on the Single-Dose Pharmacokinetics of Midazolam: Shortening the Paradigm

(2009) S. A. Stoch et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A

(2008) S. Jeong et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping

(2008) Bettina Link et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4

(2008) Shu-Feng Zhou   CURRENT DRUG METABOLISM

Limitations of Using a Single Postdose Midazolam Concentration to Predict CYP3A-Mediated Drug Interactions

(2008) Scott R. Penzak et al.   JOURNAL OF CLINICAL PHARMACOLOGY